RSV-Related Healthcare Burden: A Prospective Observational Study in a Resource-Constrained Setting

Senjuti Saha PhD[1#], Sudipta Saha SM[1,2], Naito Kanon MSc[1], Yogesh Hooda PhD[1], Mohammad Shahidul Islam PhD[1], Shuborno Islam BSc[1], Zabed Bin Ahmed MSc[1], Sheikh Wasik Rahman MPH[1], Md Jahangir Alam FCPS[3], Ataul Mustufa Anik MSc[1], Probir K Sarkar FCPS[3], Mohammed Rizwanul Ahsan, DCH[4], Md. Ruhul Amin FCPS[1], Samir K Saha PhD[1,5,#]

1. Child Health Research Foundation, Dhaka, Bangladesh
2. Department of Social and Behavioural Sciences, Harvard T. H. Chan School of Public Health, Boston, USA
3. Department of Pediatric Respiratory Medicine (Pulmonology), Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh
4. Department of Emergency, Observatory and Referral, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh
5. Department of Microbiology, Bangladesh Shishu Hospital and Institute, Dhaka, Bangladesh

Correspondence to

Senjuti Saha, PhD
Deputy Executive Director
Child Health Research Foundation
23/2 Khilji Road, Mohammadpur, Dhaka 1207, Bangladesh
Email: senjutisaha@chrfbd.org
And
Professor Samir K Saha, PhD, FAAM, FRCPath
Executive Director
Child Health Research Foundation, 23/2 Khilji Road, Mohammadpur
Dhaka 1207, Bangladesh

30 Head, Department of Microbiology,
31 Bangladesh Shishu Hospital & Institute
32 Sher-e-Bangla Nagar, Dhaka 1207, Bangladesh
33 Email: samir@chrfbd.org
34

Abstract

Background: Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalizations worldwide, straining health systems. Data gaps in resource-limited settings and limited RSV immunization impact estimates hinder policymaking.

Methods: From January to December 2019, we conducted a prospective study at Bangladesh's largest pediatric hospital to assess RSV's burden on the health system. Outcomes for RSV-positive under-five children were analyzed. We followed outcomes of children denied hospitalization due to bed shortages. Adjusted hazard ratios for children denied admission versus admitted were estimated using survival analysis. Monte Carlo simulations with a queuing model were used to estimate effects of RSV interventions on admission denials and mortality.

Findings: Of 40,664 children admitted, 31,692 were under-five; 19,940 were in study wards. Among 7,191 admitted with possible respiratory infections, 6,149 (86%) had samples taken, with 1,261 (21%) testing RSV-positive. Median age of RSV cases was 3 months, with a median hospital-stay of 5 days; 24 (1.9%) died in hospital. RSV cases accounted for 8,274 of 151,110 bed days. Additionally, of 9,169 children denied admission, outcomes were tracked for 3,928 and compared with 2,845 admitted. The hazard ratio for death was 1.56 [95%CI:1.34-1.81] for children denied versus admitted, highest within neonates at 2.27 [95%CI:1.87-2.75]. RSVpreF maternal vaccine or Nirsevimab could have reduced denials by 677 [95%PI:63-1347] and 1,289 [95%PI:684-1865], respectively, potentially preventing 130 [95%PI:-60-322] and 258 [95%PI:32-469] deaths.

Interpretation: RSV strains healthcare in Bangladesh, increasing mortality risks. Preventive interventions could lessen its impact, boosting healthcare capacity and child health in resource-limited settings.

Funding: BMGF

63 **Introduction**

64 Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infection in young
65 children. Annually, RSV infections are estimated to result in 33 million episodes, 3.6 million
66 hospitalizations, and over 100,000 deaths worldwide.[1] Low- and middle-income countries (LMICs) bear
67 a disproportionate burden of the disease, where over 95% of RSV-associated acute lower respiratory
68 infection episodes and more than 97% of RSV-attributable deaths occur.[1]
69
70 Interventions, such as maternal vaccines and long-acting monoclonal antibodies, promise to reduce
71 RSV-related morbidity and mortality.[2–6] There is also growing evidence suggesting that these
72 interventions might have broader benefits, like reducing respiratory illnesses caused by other
73 pathogens, and decreasing recurrent hospitalizations.[7–9] Policymakers are grappling with how to
74 prioritize and implement these measures, but often lack up-to-date and locally relevant
75 epidemiological data from LMICs to guide these decisions.
76
77 In Bangladesh, a densely populated lower-middle income country, with a birth cohort of almost 3
78 million, the healthcare system faces challenges due to the high burden of communicable and non-
79 communicable diseases.[10,11] Data from the country's largest pediatric hospital indicate that
80 approximately 20% of children needing hospitalization—whether for communicable or non-
81 communicable diseases—have to be turned away due to bed shortages.[12] In these settings, a high RSV
82 burden can exacerbate capacity issues while also potentially leading to adverse health outcomes for
83 children who are denied admission. Thus, it is imperative to consider both the direct and indirect
84 effects of RSV infections on child health and the broader health system when making informed policy
85 decisions.
86
87 Two multi-country studies, Aetiology of Neonatal Infections in South Asia (ANISA),[13] and Pneumonia
88 Etiology Research for Child Health (PERCH),[14] have highlighted RSV as a primary etiological agent in
89 sepsis and respiratory tract infections in Bangladesh and other countries in Asia and Africa. While these
90 studies underscore RSV's role in child morbidity in resource-constrained settings, gaps remain in

understanding the broader impact of RSV-associated hospitalizations on the healthcare capacity in resource-constrained settings.

To address the gaps in data and estimate the potential impact of RSV vaccines, we conducted a prospective, observational study in Bangladesh's largest pediatric hospital. We aimed to quantify RSV-associated hospitalizations, bed usage, and outcomes. We also aimed to assess the broader health implications for children denied admission due to bed shortages by simulating different scenarios involving RSV preventive interventions, providing crucial data to inform policy decisions.

Methods

Ethical considerations

This study was approved by the ethical review board of the Bangladesh Shishu Hospital and Institute (BSHI). For children admitted to the hospital, written consent was obtained from parents or guardians for nasopharyngeal sample collection, testing and inclusion in the study. For children denied hospitalization, data on their health outcome of children were obtained from caregivers over telephone after obtaining verbal consent.

Study Design and Setting

From January to December 2019, we conducted a prospective observational surveillance study at BSHI, located in Dhaka, Bangladesh. BSHI, with its 653-bed capacity (2019), is Bangladesh's largest pediatric hospital, offering primary to tertiary care for patients up to 18 years old. Admission decisions for the in-patient department (IPD) are made by physicians in the Emergency Room (ER).

This study had two main components: (i) active surveillance within the IPD to detect RSV infections; and (ii) active surveillance of health outcomes of patients who, despite needing hospitalization, were denied admission due to bed shortages in the IPD, and a control group of patients who were admitted to the IPD.

119 *RSV Surveillance in the IPD*

120 Children aged 0–59 months admitted to the wards selected for the study were evaluated by study
121 physicians. Inclusion criteria for this study were children hospitalized with a possible respiratory
122 infection as guided by the WHO RSV hospital-based surveillance case definition (Text S1, appendix page
123 3).[15] These study wards contained 414 beds; the remaining 239 beds of the total 653 were not included
124 because they were in wards that do not admit patients with possible infectious diseases (surgery,
125 nephrology, oncology and cardiology wards). Nasopharyngeal swabs were collected by trained nurses
126 from eligible children except those requiring support such as high-flow nasal cannula, CPAP, headbox,
127 or incubators (Table S2, appendix page 24), and tested using qPCR (Text S2, appendix page 4).
128

129 *Surveillance of Children Denied Admission in the ER*

130 Upon arrival at BSHI, families with children potentially needing hospitalization are triaged in the ER.
131 Beds are available on a first-come first-serve basis. If the physician decides that the child requires
132 hospitalization, but no beds are available, families are referred or advised to seek care elsewhere.
133 During this study, when a child could not be admitted due to bed shortages despite requiring
134 hospitalization (referred to here as “denied”), trained research assistants documented the ER
135 physician's diagnosis for the patients and collected the parents' or a family member’s contact
136 information during their hospital visit (between 8 am and 9 pm) and obtained permission to call them
137 later (Text S1). Here, “denials” refer only to denial at BSHI and do not indicate that children were
138 unable to receive care at a different hospital.
139

140 *Health Outcome Follow-Up*

141 Among the under-five children denied admission due to bed shortages and whose contact information
142 was obtained, families were selected using a computer-based randomization algorithm and contacted
143 via telephone approximately two weeks after denial of admission, and the child's health status (“alive”
144 or “deceased”), and date of death (if applicable) were recorded upon obtaining verbal consent on
145 study participation and data collection. If the child was alive during the 2-week follow-up, a second
146 follow-up call was made three months after denial of admission. In parallel, from the cohort of under-

147 five children who were admitted during the same time, children were randomly chosen for follow-up in
148 the same manner.
149
150 Survival curves were computed using the Kaplan-Meier method and crude and adjusted hazard ratios
151 were calculated using Cox Proportional-Hazards models (Text S3).
152
153 *Estimated impact of RSV preventive interventions*
154 We used queueing theory[16] and Monte Carlo simulations to understand how a reduction in RSV cases
155 requiring admission may impact: (i) strain on hospital capacity, (ii) overall denial of patients seeking
156 admission, and (iii) mortality. Our model algorithm was based on the admissions process described
157 above and simulated daily admissions and discharges through the hospital given observed and
158 hypothetical caseloads. Details of the simulations are provided in the appendix (Text S4, Figures S1,
159 S2).
160
161 *Role of funding source*
162 The funder had no role in study design, data collection, data analysis, data interpretation, writing of
163 the report, or the decision to submit this manuscript. The corresponding authors had full access to all
164 the data in the study and had final responsibility for the decision to submit for publication.
165
166 **Results**
167 *Cases Hospitalized with RSV:*
168 In 2019, a total of 49,833 children sought care at BSHI and were advised admission, of whom 40,664
169 could be admitted based on the available beds (Figure 1, Table 1). 31,692 of them were <5 years old,
170 and of them 19,940 were admitted in the screening wards. Of those admitted, 7,191 met the RSV
171 hospital-based surveillance case definition, and a sample was successfully collected from 6,149 (86%)
172 of these children. 1,042 children were not enrolled because 152 did not consent, 669 left before NP
173 swabs could be collected, and in 221 cases sample collection was not possible for various reasons such
174 as use of high-flow oxygen canula or being in a special ward (Figure 1, Table S2). 92% (5658/6149) of all
175 samples were collected within 72 hours of hospitalization (Table S3).



Figure 1. Flowchart of sample collection and patient follow-up. The figure illustrates the process of sample collection and subsequent patient follow-up for children under five admitted to BSHI or denied admission due to the unavailability of beds. *Please see appendix Table S2 for reasons why samples could not be collected.

181

182 All 6,149 samples were tested for the presence of RSV using qPCR, and of them 1,261 (21%) samples
183 tested positive. Assuming 1,042 untested eligible cases among 7,191 had the same positivity as those
184 tested, the overall proportion of all hospital admissions that were RSV positive was 4.65% or 465 RSV
185 cases per 10,000 <5 hospitalizations (95%CI:443-489).

186

187 Over 70% (882/1261) of the total RSV-positive cases were enrolled in the study during the four months
188 from June to September (Figure 2B). During July, August and September, more than 20% of the 414
189 beds were occupied by RSV-positive cases (Figure 2C).

190

191 **Table 1: Clinical attributes of <5-year children admitted to study wards by RSV status. p-values were**
192 **computed with Chi-squared tests for categorical variables (sex, case fatality rate, diagnosis), and**
193 **Kruskal-Wallis tests for the continuous variables (age, length-of-stay).** *A list of diagnoses that may
194 be included in "other" is provided in the Appendix, Table S1.

195

	Overall	RSV Positive	RSV Negative	Eligible but untested	Not eligible	p-value
Number of Patients	19940	1261	4888	1042	12749	
Sex - Female (%)	7582 (38.0)	386 (30.6)	1755 (35.9)	392 (37.6)	5049 (39.6)	<0.0001
Age in months (median [IQR])	5.00 [0.00, 16.00]	3.00 [1.00, 8.00]	2.00 [0.00, 10.00]	0.00 [0.00, 6.00]	7.00 [0.00, 21.00]	<0.0001
< 2 weeks	5448 (27.3)	72 (5.7)	1486 (30.4)	466 (44.7)	3424 (26.9)	
2 weeks - 3 months	3955 (19.8)	625 (49.6)	1214 (24.8)	262 (25.1)	1854 (14.5)	
4 - 6 months	1648 (8.3)	184 (14.6)	500 (10.2)	78 (7.5)	886 (6.9)	
7 months - 2 yrs	5693 (28.6)	312 (24.7)	1194 (24.4)	185 (17.8)	4002 (31.4)	
2 – 5 yrs	3196 (16.0)	68 (5.4)	494 (10.1)	51 (4.9)	2583 (20.3)	
In-hospital case fatality (%)	1266 (6.3)	24 (1.9)	372 (7.6)	291 (27.9)	579 (4.5)	<0.0001
Length of stay (median [IQR])	4.00 [2.00, 7.00]	5.00 [4.00, 8.00]	6.00 [3.00, 9.00]	2.00 [1.00, 4.00]	4.00 [2.00, 7.00]	<0.0001
Diagnosis Clusters (%)						

Respiratory Manifestation	5476 (27.5)	988 (78.4)	2392(48.9)	475 (45.6)	1621 (12.7)	<0.0001
Gastrointestinal Manifestation	2498 (12.5)	45 (3.6)	170 (3.5)	24 (2.3)	2259 (17.7)	<0.0001
Perinatal Asphyxia	2570(12.9)	24 (1.9)	936 (19.1)	285 (27.4)	1325(10.4)	<0.0001
Febrile Illness	1548(7.8)	25 (2.0)	209 (4.3)	24 (2.3)	1290 (10.1)	<0.0001
Preterm low-birth weight	1136 (5.7)	19 (1.5)	341 (7.0)	127 (12.2)	649 (5.1)	<0.0001
Systemic Infections	2782(14.0)	131 (10.4)	831 (17.0)	269 (25.8)	1551 (12.2)	<0.0001
Other*	12817 (64.3)	466 (37.0)	3064 (62.7)	643 (61.7)	8644 (67.8)	<0.0001

Of the positive cases, 30.6% were females. The median age of RSV-positive cases was 3 months (IQR:1.0-8.0) and 70% (881 of 1261) of the cases were within their first six months of life (Figure 3A, Table 1). 17% of infections occurred in the first four weeks of life, highlighting the vulnerability of very young babies to RSV. Median hospital stay of RSV cases was 5 days (IQR: 4-8), while median stay of all hospitalized cases was 4 days (IQR:2-7). Throughout the year, RSV cases accounted for 8,274 (5.5%) of the total 151,110 bed days observed.



Figure 2. RSV Infections and Bed Occupancy in BSHI in 2019. A. The total number of patients meeting the eligibility criteria of the study each month, and the number of samples collected from these patients. B. Percentage of tested cases that were RSV-positive each month. C. Percentage of occupied beds with RSV-positive cases across different months. The dip in bed occupancy seen in mid-August is likely because of the Eid-ul-Adha holidays.

209



210

211 **Figure 3. Age distribution of RSV-positive cases and length of hospital stay.** A. Age distribution of RSV
212 cases (n = 1,261) in weeks, where the green line represents RSV test positivity in different age groups,
213 the solid orange line indicates the median age, and the dotted orange line shows the mean age. B.
214 Length of hospital stay in days of RSV cases (n = 1,261), with the solid orange line representing the
215 median length of stay and the dotted orange line representing the mean.
216

217 *Impact of Bed Shortages on Patients Denied Admission*

218 During the study period, of the total 49,833 children requiring hospitalization, the hospital was unable
219 to admit 9,169 (18.4%) patients due to bed shortages (Figure 1). Of them, we approached and
220 collected contact information of 5,969 families for follow-up; 3,200 patients were not approached
221 because they either were >5 years of age (n=876) or came to the hospital at night when the study
222 research assistants were unavailable (n=2,324) (Figure 1). Of the families who provided contact
223 information for telephone follow-up, a random selection of 3,928 (43%) patients were contacted for
224 follow-up. Out of these, 3,435 (87%) could be successfully contacted, provided verbal consent over
225 telephone to participate and were followed up at 2 weeks (Figure 1). During the first follow-up, 504
226 (14.7%) were reported to have died. Of the 2,931 patients alive, 2,631 (89.8%) could be subsequently
227 contacted during the 3-month follow-up, and an additional 106 (4%) had died. The survival probability
228 at the end of follow-up was 0.805 (95%CI:0.791-0.819) for denied patients (Figure 4A).
229



Figure 4. Survival Analysis of Patients followed-up. A. Survival probabilities of patients denied admission and those admitted. Cases were censored at discharge if there was no follow-up or at the last successful follow-up. B. Survival curve for only RSV-positive cases: the 24 cases that resulted in in-hospital deaths, alongside the additional 205 cases that were followed up, of whom 18 subsequently died. Numbers at risk at different time points are provided below the graphs.

2,845 admitted under-five children were randomly selected for follow-up during the same time. Of them, 2,527 (89%) were successfully followed up at 2 weeks over telephone with consent. During the first follow-up, 225 (8.9%) were reported to have died (Table 2). Of the 2,302 patients alive, 1,965 (85.3%) could be subsequently contacted during the 3-month follow-up, among whom an additional 82 (4.2%) had died (Figure 4). The survival probability at the end of follow-up was 0.874 (95%CI:0.861-0.887) among those admitted (Figure 4A).

Table 2: Clinical attributes and outcome of participants admitted or denied admissions who were followed-up. The table represents data of participants for whom data could be collected. p-values were computed with Chi-squared tests for categorical variables (sex, diagnosis, mortality), and Kruskal-Wallis test for age. Diagnoses could not be collected for 18% of participants, 14-day mortality was missing for 12% (due to loss to follow u) and 90-day mortality was missing for 21% (due to loss to follow up or mortality at 14 days). *A list of diagnoses that may be included in “other” is listed in the Appendix, Table S1. 90-Day Mortality is among those alive at 14-days, and successfully followed up.

	Overall	Admitted	Denied	p-value
Number of Patients	**6772**	**2845**	**3928**	
Sex - Female (%)	2582 (38.1)	1071 (37.6)	1511 (38.5)	0.5077
Age in months (median [IQR])	3.00 [0.00, 12.00]	4.00 [0.00, 15.00]	3.00 [0.00, 11.00]	0.0069
< 2 weeks	2022 (29.9)	809 (28.4)	1213 (30.9)	<0.0001
2 weeks - 3 months	1425 (21.1)	595 (21.1)	830 (21.1)	
4 - 6 months	622 (9.2)	226 (7.9)	396 (10.1)	
7 months - 2 yrs	1869 (27.6)	764 (26.9)	1105 (28.1)	
2 - 5yrs	835 (12.3)	451 (15.9)	384 (9.8)	
ER Diagnosis Cluster (%)				
Respiratory Manifestation	1664 (26.8)	552 (22.7)	1112 (29.4)	
Gastrointestinal Manifestation	543 (8.7)	250 (10.3)	293 (7.8)	
Perinatal Asphyxia	772 (12.4)	281 (11.6)	491 (13.0)	
Febrile Illness	267 (4.3)	160 (6.6)	107 (2.8)	<0.0001
Systemic Infections	577 (9.3)	226 (9.3)	351 (9.3)	
Preterm low-birth weight	418 (6.7)	114 (4.7)	304 (8.0)	
Other*	1968 (31.7)	846 (34.8)	1122 (29.7)	
14-day Mortality (%)	729 (12.2)	225 (8.9)	504 (14.7)	<0.0001
90-day Mortality (%)*	188 (4.1)	82 (4.2)	106 (4.0)	0.8659

Overall comparison between the two groups revealed a crude hazard ratio (HR) of 1.69 (95%CI:1.48-1.94) of death in children who were denied admission compared to children who were admitted (Table 3). The HR was 1.56 (95%CI:1.34-1.81) in models adjusted for age, diagnosis (categorized as presented in Table 2), and sex. Models stratified by age groups showed that HR of death was significantly greater for denied cases among babies in their first month of life (HR 2.27 [95%CI:1.87-2.75]) but not in other age groups. When stratified by diagnosis, HR of death was significantly greater among those with perinatal asphyxia (HR 2.05 [95%CI:1.59-2.65]), preterm low-birth-weight (HR 2.78 [95%CI:1.99-3.87]).

262 **Table 3: Hazard ratio (HR) of denied vs admitted participants adjusted by age, sex, and diagnosis.** *A
263 list of diagnoses that may be included in "other" is listed in the Appendix, Table S1.
264

Adjusted by	Strata	HR [95% CI]
		1.69 [1.48, 1.69]
Age, Sex, Diagnosis		**1.56 [1.34, 1.81]**
Sex, Diagnosis	< 1 month	**2.27 [1.87, 2.75]**
Sex, Diagnosis	2-3 months	0.73 [0.53, 1.00]
Sex, Diagnosis	4 months - 1 year	1.27 [0.67, 2.40]
Sex, Diagnosis	1-5 years	0.71 [0.43, 1.16]
Age, Diagnosis	Male	**1.76 [1.44, 2.15]**
Age, Diagnosis	Female	**1.30 [1.03, 1.63]**
Age, Sex	Respiratory Manifestation	0.95 [0.73, 1.23]
Age, Sex	Perinatal Asphyxia	**2.05 [1.59, 2.65]**
Age, Sex	Systemic Infections	0.82 [0.61, 1.09]
Age, Sex	Preterm low-birth-weight	**2.78 [1.99, 3.87]**
Age, Sex	Febrile Illness	1.44 [0.20, 10.28]
Age, Sex	Gastrointestinal Manifestation	2.16 [0.84, 5.54]
Age, Sex	Other*	**1.35 [1.17, 1.56]**

265
266
267 *Mortality among RSV-positive cases*
268 Of the total 1,261 RSV-positive cases recorded in this study, 24 (1.9%) died during their stay at the
269 hospital (Table 1). Median age of these cases was 130 days (IQR:77-175). While the study was not
270 designed to specifically follow up RSV-positive cases, of the 2,527 admitted children randomly selected
271 and successfully followed up, there were 205 RSV-positive cases. Of these, 18 children died within the
272 90-day follow-up period, six of whom were also recorded as hospital deaths above. This brought the
273 total number of deaths recorded in this study to 36. Details of all cases are provided in the appendix
274 (Table S4). The overall median age was 116.5 days (IQR:69.5-220.3). Considering both in-hospital case

275 fatality of all admissions that tested positive for RSV and mortality during follow-up of a subset of
276 cases, survival decreased substantially over time, with a 90-day survival probability of 0.901
277 (95%CI:0.865-0.938) at the end of the follow-up period (Figure 4B). The most common final diagnosis
278 was pneumonia/bronchopneumonia (22 cases), frequently associated with additional conditions like
279 sepsis (9 cases), and congenital heart disease (12 cases). RSV cannot be attributed as the underlying
280 cause of death for all these cases, as this study was not designed to establish a causal link between RSV
281 and mortality.
282
283 **Potential Impact of RSV preventive interventions**
284 In Monte Carlo simulations of hospital admissions and denials for the baseline scenario, based on the
285 empirical data and a 650-bed capacity, a median of 49,726 children required admissions (95%
286 prediction intervals (PI): 49,355-50,082), and 9,283 (95%PI:8,861-9,714) cases were denied admission
287 over the year. This was in concordance with the true burden of total cases requiring admission and
288 denials – 49,833 and 9,169, respectively. In the scenario where RSVpreF maternal vaccine is introduced
289 with an estimated 38.2% reduction in RSV cases requiring hospitalization (Text S4), 48,972
290 (95%PI:48,632-49,317) patients required admission, and 8,571 patients were denied admission
291 (95%PI:8,173-8980) – a 1.19 percentage point reduction in median proportion of cases that were
292 denied admissions across simulations (Figure 5A). In the Nirsevimab scenario, with an estimated 69%
293 reduction in RSV cases requiring hospitalization (Text S4), 48,367 (95%PI:48,006 - 48,731) patients
294 required admission, and 7,991 patients were denied admission (95%PI:7,574-8,416) – a 2.2 percentage
295 point reduction (Figure 5A). Figure 5B demonstrates the estimated effects of these interventions on
296 overall mortality. Figures 5C and D compare these interventions with different bed capacities,
297 demonstrating how reducing RSV cases and increasing capacity produce similar effects. Overall, there
298 were 6,970 deaths (95%PI:6832-7117) in the baseline scenario, 6,832 deaths (95%PI:6693-6973) in the
299 RSVpreF vaccination scenario, and 6,727 deaths (95%PI:6576-6862) in the Nirsevimab scenario. This
300 corresponded to an estimated median difference in deaths of 130 (95%PI:-60-322) and 258 (95%PI:32-
301 469), respectively. Supplementary analyses suggested a linear relationship between magnitude of RSV
302 burden reduction and denial rates, holding other parameters of the system constant (Figure S3).
303



Figure 5. Impact of RSV Preventive Interventions on Hospital Utilization and 90-day Mortality Rates of all children who require admission at BSHI. Effects of a RSVpreF and Nirsevimab on RSV admissions, showing its impact on proportion of hospital denial (A), 90-day mortality proportion (B), total hospital denials (C) and total deaths (D) among children under five. The plots C and D compare mortality against the effective increase in available beds, demonstrating how reducing RSV cases is akin to increasing bed capacity.

312 **Discussion**

313 Informed decision-making on interventions to prevent RSV infections in young infants requires
314 contemporary, locally relevant epidemiological data. Our study demonstrates RSV's significant impact
315 on healthcare resources in Bangladesh, a country with a high infectious disease burden and demand
316 for pediatric care amid resource limitations.[12]

317

318 Our study recorded a 21% RSV positivity rate among 6,149 patients admitted with respiratory illnesses
319 to Bangladesh's largest pediatric hospital, corresponding to 465 RSV cases per 10,000 admissions of
320 under-five children. The median age of RSV-confirmed cases was 3 months. These findings align with
321 the PERCH study, which reported 31.2% of children hospitalized with respiratory infections in
322 Bangladesh tested positive for RSV.[14,17]

323

324 The in-hospital case fatality for RSV-positive cases was 1.9%. Among 205 randomly selected cases
325 followed for up to 90 days post-hospitalization, 18 deaths were recorded. However, these cases had
326 notable comorbidities, and this study was not designed to attribute these deaths solely to RSV
327 infection. The median age of all recorded RSV-associated deaths was 116 days or 3.8 months. In the
328 Child Health and Mortality Prevention Surveillance (CHAMPS) study, a community-based study not
329 limited to in-hospital deaths, RSV was found in 5.5% of all deaths, with variability across countries:
330 9.7% in Mali, 10.7% in Ethiopia, and 2% in Bangladesh.[18] Half of the RSV-associated deaths in the
331 CHAMPS study occurred in infants younger than six months, highlighting the vulnerability of young
332 infants to severe RSV outcomes.

333

334 Beyond the direct impact of RSV infections, our findings also demonstrate the considerable burden of
335 infections on the healthcare system. For at least three months during the study year, RSV cases
336 occupied more than 20% of the beds under observation. Median hospital stay for RSV-positive cases
337 was 5 days—longer than the overall median length of stay of 4 days for all admitted patients. In 2019,
338 RSV cases accounted for 8,274 of the total 151,110 bed days observed. Despite being the largest
339 pediatric tertiary hospital with 653 beds, BSHI faces bed shortages often forcing clinicians to deny
340 admission to sick children.[12] We followed over 5,000 admitted and denied children for up to 90 days to

341 determine the difference in health outcomes and the wider effects of high-burden infections like RSV
342 on the healthcare system. The cumulative mortality proportion for children denied admission was
343 19.5%, significantly higher than the 12.6% among those admitted. The survival probability at the end of
344 follow-up was 0.874 among those admitted, and 0.805 among those denied admission.
345
346 The HR for death was 1.56 among children denied admission compared to those admitted, adjusted for
347 age, diagnosis, and sex. The highest mortality risk was observed in neonates requiring hospitalization
348 within their first month of life, with an HR of 2.27. This disparity highlights the essential role of timely
349 healthcare access in determining child survival outcomes. Monte Carlo simulations of a queueing
350 model helped us characterize hypothetical scenarios with different bed capacities and numbers of
351 patients requiring admission. Were a RSVpreF maternal vaccine or Nirsevimab monoclonal antibody in
352 use, it is estimated to have reduced deaths by 130 and 258, respectively, during the study year among
353 patients requiring admission to the hospital. While the variability of these estimates was large and
354 overlapping, the differences in admission denial rates between scenarios were significant.
355
356 Bed shortages are a pressing issue across many LMICs. In Bangladesh, the bed rate of 0.8 per 1,000
357 population is notably lower than in developed countries, such as 2.9 in the USA and 2.5 in the UK.[19]
358 With limited infrastructure, preventive strategies are essential. While vaccine introductions and health
359 system improvements over recent decades have reduced under-five mortality in Bangladesh, the rate
360 remains high at 33 deaths per 1,000 live births, highlighting the need for more robust disease
361 prevention.[20] Given the substantial proportion of beds occupied by RSV cases during peak periods, an
362 RSV maternal vaccine could significantly improve bed availability for critically ill infants. Additionally,
363 administration of monoclonal antibodies, such as Nirsevimab,[3] in neonates and infants can also be
364 effective, particularly given high preterm birth rates in Bangladesh.[21] However, cost and logistical
365 challenges complicate the adoption of monoclonal antibody treatments in LMICs like Bangladesh.[22,23]
366
367 Global data from various countries have shown shifts in RSV outbreak patterns during and after the
368 COVID-19 pandemic.[24] While this study was conducted in 2019, before the COVID-19 pandemic, recent
369 reports from Bangladesh suggest that RSV cases have returned to pre-pandemic levels. A report from

370 the Government of Bangladesh highlights a peak in RSV cases among children under five from October
371 2022 to March 2023, with an average positivity rate of 49% in severe acute respiratory infection cases
372 during that period.[25] Another study examining RSV-associated deaths from August 2009 to March
373 2022, found no significant difference in RSV detection rates among deaths before and during the
374 COVID-19 pandemic.[26]

375 This study has certain limitations to consider. It was conducted in a single hospital, potentially limiting
376 generalizability. Multi-site research could offer a more comprehensive view of the RSV burden across
377 Bangladesh and South Asia. However, as the largest provider of tertiary pediatric care in the country,
378 this hospital's data is still highly informative. In addition, data collection was limited to one year,
379 meaning that the simulation could only account for RSV's 2019 seasonal outbreak pattern. Unlike
380 countries in temperate regions, with well-defined RSV seasons, equatorial countries like Bangladesh
381 experience varied RSV peaks—sometimes in winter, summer, or even twice a year—making multi-year
382 data crucial for modeling seasonal variability.[27,28] Additionally, RSV peaks can overlap with other
383 endemic diseases, such as dengue[29] and typhoid[30], which have unpredictable seasonal patterns,
384 complicating generalizable pattern identification even with extended data. The study also did not
385 assess concurrent infections with RSV or confirm deaths directly attributed to RSV. Furthermore,
386 sample attrition and assumptions in the simulation models could introduce bias. Although we achieved
387 a ~67% follow-up rate for both admitted and denied cases, those lost to follow-up may differ in
388 important ways. During sampling, nasopharyngeal swabs were not collected from children on
389 extensive support, such as high-flow oxygen, possibly underestimating most severe RSV cases with
390 adverse outcomes. In our simulations, we assumed non-study wards had similar seasonal admissions
391 patterns and that overnight denials, not included, were similar to daytime ones. However, children
392 presenting at night, when research assistants were unavailable, may represent a sicker cohort, as
393 emergencies often occur during these hours. This could result in an underestimation of mortality risks
394 associated with hospital denials. As we did not assess care-seeking after denial from BSHI, we cannot
395 disentangle the impact of treatment delay and/or inability to access hospital care. Finally, human
396 factors could have influenced clinicians' admission decisions during times of bed scarcity even though
397 such decisions should theoretically be unaffected by such constraints.

398 Despite the limitations, the global health implications of this study are significant. This study
399 underscores the critical role of RSV preventive interventions, such as vaccines and monoclonal
400 antibodies, in reducing the disease burden in resource-limited settings. By preventing RSV-related
401 hospitalizations, vaccination programs could alleviate seasonal surges in bed occupancy, providing
402 much-needed relief to overstretched healthcare systems. Additionally, our findings highlight the
403 broader issue of hospital bed shortages, which remain a significant barrier to effective care in many
404 LMICs. Results support the prioritization of RSV prevention programs and expansion of hospital
405 infrastructure to address persistent capacity challenges, improve healthcare access, and enhance child
406 health outcomes in low-resource settings.

407

408 **Declaration of Interests**

409 The authors declare no conflict of interest.

410

411 **Author contributions**

412 S.S. contributed to conceptualization, funding acquisition, study design, implementation, monitoring,
413 data analysis, drafting the initial manuscript, and preparation of figures. Su.S. was involved in data
414 analysis, preparation of figures, and manuscript editing. N.K. contributed to data analysis and editing.
415 Y.H. participated in data analysis, preparation of figures, and manuscript editing. M.S.I. was responsible
416 for analysis and coordination of the study, and also contributed to editing. S.I. carried out specimen
417 extraction and PCR testing. Z.B.A. and S.W.R. coordinated and trained doctors and nurses, assisted in
418 the implementation of the study, in addition to contributing to manuscript editing. M.J.A. was involved
419 in monitoring and management activities, as well as editing. A.M.A. performed data cleaning. P.K.S.
420 contributed to management and patient data analysis. M.R.A. was involved in implementation and
421 management. M.R.A. contributed to editing. S.K.S. contributed to conceptualization, funding
422 acquisition, study design, implementation, monitoring, and manuscript editing. All authors reviewed
423 the manuscript and agreed on the contents.

424

425 **Acknowledgments**

We are deeply grateful for the contributions and support of Anannya Barman Jui, Sira Jam Munira, Md. Hafizur Rahman, Shumaiya Ferdaus, Prama Dewan, Ayesha Rahman, Kazi Shammin Azmery Shalda, Shamsun Nahar, Rumana Khan Nitu, Anamika Mazumder, Syeda Mahfuza Zinat, Liza Nath, Tasmim Sultana, Shamima Tarafder, Asyia Akter, Faujiya Khanam Luna, Fatema Akter, Shali Akter, Israt Jahan, Ms. Razia Sultana , Sharmin Jahan, Asheka Shah Munmun, Kaniz Fatema Prity, Md. Shafiqul Islam, Roly Malakar, Shakila Yeasmin and Mahmudul Hasan Sohel. Their collaboration at various stages of the study ensured its successful completion.

Declaration of Generative AI and AI-assisted technologies in the writing process

During the preparation of this work the authors used ChatGPT to check grammar, spellings, and improve readability of the manuscript. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

References

1 Li Y, Wang X, Blau DM, *et al.* Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet* 2022; **399**: 2047–64.

2 Baral R, Higgins D, Regan K, Pecenka C. Impact and cost-effectiveness of potential interventions against infant respiratory syncytial virus (RSV) in 131 low-income and middle-income countries using a static cohort model. *BMJ Open* 2021; **11**: e046563.

3 Muller William J., Madhi Shabir A., Seoane Nuñez Beatriz, *et al.* Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. *New England Journal of Medicine* 2023; **388**: 1533–4.

4 Hammitt LL, Dagan R, Yuan Y, *et al.* Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. *New England Journal of Medicine* 2022; **386**: 837–46.

5 Commissioner O of the. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. FDA. 2023; published online Aug 22. https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants (accessed April 13, 2024).

6 Kampmann B, Madhi SA, Munjal I, *et al.* Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. *New England Journal of Medicine* 2023; **388**: 1451–64.

456 7 Zar HJ, Nduru P, Stadler JAM, *et al.* Early-life respiratory syncytial virus lower respiratory tract
457 infection in a South African birth cohort: epidemiology and effect on lung health. *The Lancet Global*
458 *Health* 2020; **8**: e1316–25.

459 8 Abreo A, Wu P, Donovan BM, *et al.* Infant Respiratory Syncytial Virus Bronchiolitis and Subsequent
460 Risk of Pneumonia, Otitis Media, and Antibiotic Utilization. *Clin Infect Dis* 2020; **71**: 211–4.

461 9 Feikin DR, Karron RA, Saha SK, *et al.* The full value of immunisation against respiratory syncytial virus
462 for infants younger than 1 year: effects beyond prevention of acute respiratory illness. *The Lancet*
463 *Infectious Diseases* 2023; **0**. DOI:10.1016/S1473-3099(23)00568-6.

464 10 Bangladesh | Gavi, the Vaccine Alliance. 2018; published online Nov 29.
465 https://www.gavi.org/programmes-impact/country-hub/south-east-asia/bangladesh (accessed April
466 13, 2024).

467 11 Islam SMS, Uddin R, Das S, *et al.* The burden of diseases and risk factors in Bangladesh, 1990–2019: a
468 systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Global Health* 2023; **11**:
469 e1931–42.

470 12 Saha S, Santosham M, Hussain M, Black RE, Saha SK. Rotavirus Vaccine will Improve Child Survival by
471 More than Just Preventing Diarrhea: Evidence from Bangladesh. *Am J Trop Med Hyg* 2018; **98**: 360–
472 3.

473 13 Saha SK, Schrag SJ, El Arifeen S, *et al.* Causes and incidence of community-acquired serious
474 infections among young children in south Asia (ANISA): an observational cohort study. *The Lancet*
475 2018; **392**: 145–59.

476 14 O'Brien KL, Baggett HC, Brooks WA, *et al.* Causes of severe pneumonia requiring hospital admission
477 in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study.
478 *The Lancet* 2019; **394**: 757–79.

479 15 Case definitions. https://www.who.int/teams/global-influenza-programme/global-respiratory-
480 syncytial-virus-surveillance/case-definitions (accessed Jan 6, 2024).

481 16 Palvannan RK, Teow KL. Queueing for Healthcare. *J Med Syst* 2012; **36**: 541–7.

482 17 Brooks WA, Zaman K, Goswami D, *et al.* The Etiology of Childhood Pneumonia in Bangladesh. *Pediatr*
483 *Infect Dis J* 2021; **40**: S79–90.

484 18 Blau DM, Baillie VL, Els T, *et al.* Deaths Attributed to Respiratory Syncytial Virus in Young Children in
485 High-Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance
486 (CHAMPS). *Clin Infect Dis* 2021; **73**: S218–28.

487 19 World Bank Open Data. World Bank Open Data. https://data.worldbank.org (accessed April 21,
488 2024).

489 20 SDG Tracker. https://sdg.gov.bd/page/indicator-wise/1/30/3/0#1 (accessed April 21, 2024).

490 21 Ohuma EO, Moller A-B, Bradley E, *et al.* National, regional, and global estimates of preterm birth in
491 2020, with trends from 2010: a systematic analysis. *The Lancet* 2023; **402**: 1261–71.

492 22 Sparrow E, Adetifa I, Chaiyakunapruk N, *et al.* WHO preferred product characteristics for monoclonal
493 antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key
494 considerations for global use. *Vaccine* 2022; **40**: 3506–10.

495 23 Zar HJ, Piccolis M, Terstappen J, *et al.* Access to highly effective long-acting RSV-monoclonal
496 antibodies for children in LMICs—reducing global inequity. *The Lancet Global Health* 2024; **12**:
497 e1582–3.

498 24 Bardsley M, Morbey RA, Hughes HE, *et al.* Epidemiology of respiratory syncytial virus in children
499 younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical,
500 and syndromic surveillance: a retrospective observational study. *The Lancet Infectious Diseases*
501 2023; **23**: 56–66.

502 25 2023-05-31-17-02-bed461250ff1b439a0338ab3ddfea682.pdf.
503 https://heu.portal.gov.bd/sites/default/files/files/heu.portal.gov.bd/page/364480c2_26f9_4bbb_bf
504 71_8b4ac613d96a/2023-05-31-17-02-bed461250ff1b439a0338ab3ddfea682.pdf (accessed April 13,
505 2024).

506 26 Hassan MZ, Islam MA, Haider S, Shirin T, Chowdhury F. Respiratory Syncytial Virus-Associated
507 Deaths among Children under Five before and during the COVID-19 Pandemic in Bangladesh. *Viruses*
508 2024; **16**: 111.

509 27 Bloom-Feshbach K, Alonso WJ, Charu V, *et al.* Latitudinal variations in seasonal activity of influenza
510 and respiratory syncytial virus (RSV): a global comparative review. *PLoS One* 2013; **8**: e54445.

511 28 Li Y, Reeves RM, Wang X, *et al.* Global patterns in monthly activity of influenza virus, respiratory
512 syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. *Lancet Glob Health*
513 2019; **7**: e1031–45.

514 29 Chen Y, Xu Y, Wang L, *et al.* Indian Ocean temperature anomalies predict long-term global dengue
515 trends. *Science* 2024; **384**: 639–46.

516 30 Saad NJ, Lynch VD, Antillón M, Yang C, Crump JA, Pitzer VE. Seasonal dynamics of typhoid and
517 paratyphoid fever. *Sci Rep* 2018; **8**: 6870.

518

519